References from scientific journals

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.

Tang HJ, Wang JH, Lai CC. Tang HJ, et al. Medicine (Baltimore). 2020 Jul 17;99(29):e21223. doi: 10.1097/MD.0000000000021223. Medicine (Baltimore). 2020. PMID: 32702892 Free PMC article. Clinical Trial.

The early clinical response rate was 89.3% and 90.5% among lefamulin and moxifloxacin group, respectively. Lefamulin was noninferior to moxifloxacin (89.3% vs 90.5%, RR: 0.99, 95% CI: 0.95-1.02, I = 0%). ...Lefamulin was associated with a similar risk of adverse eve …
The early clinical response rate was 89.3% and 90.5% among lefamulin and moxifloxacin group, respectively. Lefamulin was noninferior …

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?

Karampela I, Dalamaga M. Karampela I, et al. Arch Med Res. 2020 Oct;51(7):741-742. doi: 10.1016/j.arcmed.2020.06.004. Epub 2020 Jun 6. Arch Med Res. 2020. PMID: 32546446 Free PMC article.

A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by exhibiting stronger capacity for binding to its main protease than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug. ...N …
A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by e …

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. Bennett AC, et al. Expert Opin Drug Saf. 2019 Nov;18(11):1055-1063. doi: 10.1080/14740338.2019.1665022. Epub 2019 Sep 18. Expert Opin Drug Saf. 2019. PMID: 31500468 Review.

Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the most commonly prescribed antibiotics. ...
Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the mo …

Moxifloxacin Labeling-Based Multiphoton Microscopy of Skin Cancers in Asians.

Chang H, Jang WH, Lee S, Kim B, Kim MJ, Kim WO, Ryoo YW, Oh BH, Kim KH. Chang H, et al. Lasers Surg Med. 2020 Apr;52(4):373-382. doi: 10.1002/lsm.23138. Epub 2019 Jul 23. Lasers Surg Med. 2020. PMID: 31338864

Moxifloxacin MPM imaged cells in the skin similarly to acridine orange-based FCM. Moxifloxacin MPM of various human skin cancer specimens imaged their specific cellular features. ...
Moxifloxacin MPM imaged cells in the skin similarly to acridine orange-based FCM. Moxifloxacin MPM of various human skin cance …

Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.

Bowen RC, Zhou AX, Bondalapati S, Lawyer TW, Snow KB, Evans PR, Bardsley T, McFarland M, Kliethermes M, Shi D, Mamalis CA, Greene T, Rudnisky CJ, Ambati BK. Bowen RC, et al. Br J Ophthalmol. 2018 Sep;102(9):1268-1276. doi: 10.1136/bjophthalmol-2017-311051. Epub 2018 Jan 11. Br J Ophthalmol. 2018. PMID: 29326317 Free PMC article.

The average weighted postoperative endophthalmitis incidence rates with intracameral cefuroxime, moxifloxacin and vancomycin were 0.0332%, 0.0153% and 0.0106%, respectively. ...Most studies had low to moderate risk of bias. The safety analysis showed minimal toxicity for …
The average weighted postoperative endophthalmitis incidence rates with intracameral cefuroxime, moxifloxacin and vancomycin were 0.0 …

Systemic Moxifloxacin in Streptococcus viridans Endophthalmitis.

Nam KY, Lee SJ, Kim JY. Nam KY, et al. Ocul Immunol Inflamm. 2019;27(1):155-161. doi: 10.1080/09273948.2017.1353103. Epub 2017 Oct 5. Ocul Immunol Inflamm. 2019. PMID: 28981383

RESULTS: Clinical scores and log(10)CFU/ml values were lower in moxifloxacin group on all examination days. Histopathologic examination showed less inflammation and relatively well-preserved retina in the moxifloxacin group. CONCLUSIONS: Systemic moxifloxacin …
RESULTS: Clinical scores and log(10)CFU/ml values were lower in moxifloxacin group on all examination days. Histopathologic examinati …

Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections.

LLopis B, Funck-Brentano C, Tissot N, Bleibtreu A, Jaureguiberry S, Fourniols E, Aubry A, Zahr N. LLopis B, et al. J Pharm Biomed Anal. 2020 May 10;183:113137. doi: 10.1016/j.jpba.2020.113137. Epub 2020 Feb 1. J Pharm Biomed Anal. 2020. PMID: 32086125 Free article.

The calibration curves were linear over the range from 0.5-30 mug/mL for levofloxacin, ciprofloxacin, moxifloxacin and rifampicin with linear regression coefficients above 0.995 for all analytes. ...CONCLUSION: A simple, rapid, and selective liquid chromatography-tandem ma …
The calibration curves were linear over the range from 0.5-30 mug/mL for levofloxacin, ciprofloxacin, moxifloxacin and rifampicin wit …

Injection volume and intracameral moxifloxacin dose.

Arshinoff SA, Modabber M. Arshinoff SA, et al. J Cataract Refract Surg. 2020 Jan;46(1):162-163. doi: 10.1097/j.jcrs.0000000000000007. J Cataract Refract Surg. 2020. PMID: 32050249 No abstract available.


High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. Dorman SE, et al. Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. Contemp Clin Trials. 2020. PMID: 31981713 Free PMC article. Clinical Trial.

Both of the four-month regimens contain high-dose rifapentine instead of rifampin, with ethambutol replaced by moxifloxacin in one regimen. All drugs are administered seven days per week, and under direct observation at least five days per week. ...
Both of the four-month regimens contain high-dose rifapentine instead of rifampin, with ethambutol replaced by moxifloxacin in one re …

Ocular delivery of moxifloxacin-loaded liposomes.

Ferreira KSA, Santos BMAD, Lucena NP, Ferraz MS, Carvalho RSF, Duarte Júnior AP, Magalhães NSS, Lira RPC. Ferreira KSA, et al. Arq Bras Oftalmol. 2018 Nov./Dec.;81(6):510-513. doi: 10.5935/0004-2749.20180090. Epub 2018 Sep 13. Arq Bras Oftalmol. 2018. PMID: 30231158 Free article.

RESULTS: The average size of the liposomes containing moxifloxacin was 60.5 0.72 nm with a particle size distribution of 0.307. The encapsulation efficiency of moxifloxacin in liposomes was 92.24 0.24%. The results of an in vivo release study of liposomes containing …
RESULTS: The average size of the liposomes containing moxifloxacin was 60.5 0.72 nm with a particle size distribution of 0.307. The e …